Minerva Neurosciences, Inc (NERV) Stock

About Minerva Neurosciences, Inc

Minerva Neurosciences, Inc. functions as a biopharmaceutical firm in the clinical development stage, primarily dedicated to uncovering and bringing to market novel therapeutic options for disorders affecting the central nervous system. Its portfolio of experimental treatments notably features roluperidone, an investigational drug aimed at managing schizophrenia, alongside MIN-301, a soluble recombinant variant of the neuregulin-1b1 protein, which is being explored for its potential in treating Parkinson's disease and various other neurodegenerative conditions. The company has a contractual licensing agreement with Mitsubishi Tanabe Pharma Corporation, authorizing the worldwide development, distribution, and import of roluperidone, with the explicit exclusion of the Asian continent. Established in 2007, this organization initially operated as Cyrenaic Pharmaceuticals, Inc. before undergoing a name change to Minerva Neurosciences, Inc. in 2013. Its corporate headquarters are located in Waltham, Massachusetts.

Minerva Neurosciences, Inc is led by CEO Remy Luthringer, employs 8 people, headquartered in US, publicly traded since 2014.

Minerva Neurosciences, Inc (NERV) stock trades at $2.30 with a market capitalization of $109.82M. The stock is valued at a negative price-to-earnings (P/E) ratio of -0.08, reflecting a net loss over the last twelve months, a negative price-to-book of -0.54, reflecting negative shareholders' equity, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $2.24 and $8.80, and currently trades 73.9% below its 52-week high.

On profitability, Minerva Neurosciences, Inc generates a return on equity (ROE) of 250.02% (not meaningful, as shareholders' equity is negative), return on capital employed of -38.56%.

Official website: www.minervaneurosciences.com

Minerva Neurosciences, Inc by the numbers, 2016–2025

Between 2016 and 2025 Minerva Neurosciences, Inc reported revenue of $0 rising to $0. Compounded, revenue has grown —% a year over five years, —% over three, —% over the last twelve months. Net profit fell to $-293.0M.

On a trailing twelve-month basis to Jun '26, revenue is $0 and net profit $-395.0M.

Borrowings rose from $9.0M to $65.0M, cash from operations was $-13.5B in the latest year, positive in 1 of the last 10.

Return on equity has averaged -30.8% over five years, and was 207.8% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Minerva Neurosciences, Inc (NERV) — frequently asked questions